DelveInsight’s, “Hepatic Tumor Pipeline Insight 2025”report provides comprehensive insights about 75+ companies and 75+ pipeline drugs in Hepatic Tumor pipeline landscape. It covers the Hepatic Tumor pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Hepatic Tumor pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest drugs and treatment options in the Hepatic Tumor Pipeline. Dive into DelveInsight’s comprehensive report today! @ Hepatic Tumor Pipeline Outlook

Key Takeaways from the Hepatic Tumor Pipeline Report

• On 22 August 2025, Massachusetts General Hospital announced a study is studying a drug in combination with radiation therapy as a possible treatment for hepatic metastases from colorectal cancer. A phase I clinical trial tests the safety of an investigational intervention and also tries to define the appropriate dose of the investigational drug to use for further studies. “Investigational” means that the intervention is being studied.
• On 12 August 2025, Eureka Therapeutics Inc. conducted a study is to evaluate an investigational ARTEMIS® ECT204 T-cell therapy in adult patients with GPC3-positive advanced hepatocellular carcinoma (HCC). In this study, a patient’s T cells are collected and genetically modified to express Eureka’s proprietary anti-GPC3 ARTEMIS T cell receptors (AbTCR). These modified T cells are then reintroduced into the patient to specifically seek out and destroy GPC3-expressing cancer cells.
• DelveInsight’s Hepatic Tumor pipeline report depicts a robust space with 75+ active players working to develop 75+ pipeline therapies for Hepatic Tumor treatment.
• The leading Hepatic Tumor Companies such as Can Fite Biopharma, MiNA Therapeutics, Medivir AB, Janssen Research & Development, LLC, Etnova Therapeutics Corp., SillaJen Biotherapeutics, Akeso Biopharma, Shanghai Junshi Biosciences, Genmab/Janssen Biotech, Bio-Thera Solutions, Ocuphire Pharma, Surface Oncology, Genoscience, Onyx Pharmaceuticals, Qurient Co., Ltd., Kowa Company, Ltd., and Eureka Therapeutics Inc and others.
• Promising Hepatic Tumor Pipeline Therapies such as Atezolizumab, Bevacizumab 15 mg/kg, Tiragolumab, NIK-333(peretinoin), Sorafenib, SonoVue®, Talaporfin sodium, NV1020, Pemetrexed, and others.

Stay ahead with the most recent pipeline outlook for Hepatic Tumor. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Hepatic Tumor Treatment Drugs

Hepatic Tumor Emerging Drugs Profile

• Namodenoson: Can Fite Biopharma

Namodenoson is a small molecule A3 adenosine receptor (A3AR) agonist. It is an oral drug currently being developed for the treatment of oncology diseases including advanced liver cancer(hepatocellular carcinoma), pancreatic cancer and metabolic associated steatohepatitis (MASH). Currently it is in Phase III stage of clinical trial evaluation to treat Hepatocellular Carcinoma.

• MTL CEBPA: MiNA Therapeutics

MTL-CEBPA is a novel medicine being developed as a combination therapy in cancer. MTL-CEBPA is designed to reduce immune suppression of myeloid cells by restoring C/EBP-a protein to normal levels using the RNA Activation mechanism. The drug candidate uses the RNA interference mechanism of action. Currently being evaluated in the Phase II studies for the treatment of Hepatic Tumor.

• Amivantamab: Janssen Research & Development, LLC

Amivantamab is a fully-human EGFR-MET bispecific antibody with immune cell-directing activity that targets tumors with activating and resistance EGFR mutations and MET mutations and amplifications. The drug is based on antibody-dependent cell cytotoxicity mechanism of action. The drug is in Phase II stage of clinical trials for the treatment of Hepatic Tumor.

• Fostroxacitabine bralpamide: Medivir AB

Fostroxacitabine bralpamide is a small molecule a type of smart chemotherapy that delivers the cell-killing compound selectively to the tumor while minimizing the harmful effect on normal cells. being developed by Medivir AB. It works as Nucleotide DNA polymerase inhibitor. The drug candidate is administered through oral route. Currently the drug is being evaluated in Phase I/II for the treatment of Hepatic Tumor.

• ETN101: Etnova Therapeutics Corp.

ETN101 is a synthetic drug candidate designed to be a best-in-class anticancer agent targeting hepatocellular carcinoma. It is being developed with the aim of preoccupying the market for both first-line and follow-up treatments of hepatocellular carcinoma with its high rate of complete remission and safety. It inhibits protein activity using FLT3/KIT/VEGFR2/PDGFRB tyrosine kinase inhibitors and its downstream signaling pathways: PI3K/AKT and RAS-MAPK, working as multiple tyrosine kinase inhibitors (mTKI). The drug is in Phase I stage of clinical trials for the treatment of Hepatic Tumor.

The Hepatic Tumor Pipeline Report Provides Insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Hepatic Tumor with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Hepatic Tumor Treatment.
• Hepatic Tumor Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Hepatic Tumor Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Hepatic Tumor market

Explore groundbreaking therapies and clinical trials in the Hepatic Tumor Pipeline. Access DelveInsight’s detailed report now! @ New Hepatic Tumor Drugs

Hepatic Tumor Companies

Can Fite Biopharma, MiNA Therapeutics, Medivir AB, Janssen Research & Development, LLC, Etnova Therapeutics Corp., SillaJen Biotherapeutics, Akeso Biopharma, Shanghai Junshi Biosciences, Genmab/Janssen Biotech, Bio-Thera Solutions, Ocuphire Pharma, Surface Oncology, Genoscience, Onyx Pharmaceuticals, Qurient Co., Ltd., Kowa Company, Ltd., and Eureka Therapeutics Inc and others.

Hepatic Tumor Pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• intravenous
• Subcutaneous
• Topical.

Hepatic Tumor Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Unveil the future of Hepatic Tumor Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight’s expert analysis @ Hepatic Tumor Market Drivers and Barriers

Scope of the Hepatic Tumor Pipeline Report

• Coverage- Global
• Hepatic Tumor Companies- Can Fite Biopharma, MiNA Therapeutics, Medivir AB, Janssen Research & Development, LLC, Etnova Therapeutics Corp., SillaJen Biotherapeutics, Akeso Biopharma, Shanghai Junshi Biosciences, Genmab/Janssen Biotech, Bio-Thera Solutions, Ocuphire Pharma, Surface Oncology, Genoscience, Onyx Pharmaceuticals, Qurient Co., Ltd., Kowa Company, Ltd., and Eureka Therapeutics Inc and others.
• Hepatic Tumor Pipeline Therapies- Atezolizumab, Bevacizumab 15 mg/kg, Tiragolumab, NIK-333(peretinoin), Sorafenib, SonoVue®, Talaporfin sodium, NV1020, Pemetrexed, and others.
• Hepatic Tumor Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Hepatic Tumor Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Get the latest on Hepatic Tumor Therapies and clinical trials. Download DelveInsight’s in-depth pipeline report today! @ Hepatic Tumor Companies, Key Products and Unmet Needs

Table of Contents

1. Introduction
2. Executive Summary
3. Hepatic Tumor: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Late Stage Products (Phase III)
7. Comparative Analysis
8. Namodenoson: Can Fite Biopharma
9. Mid Stage Products (Phase II)
10. MTL CEBPA : MiNA Therapeutics
11. Early Stage Products (Phase I)
12. Comparative Analysis
13. ETN101: Etnova Therapeutics Corp.
14. Inactive Products
15. Hepatic Tumor Key Companies
16. Hepatic Tumor Key Products
17. Hepatic Tumor – Unmet Needs
18. Hepatic Tumor – Market Drivers and Barriers
19. Hepatic Tumor – Future Perspectives and Conclusion
20. Hepatic Tumor Analyst Views
21. Hepatic Tumor Key Companies
22. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/hepatic-tumor-pipeline-insight